Clinical trials: Decitabine
Acute Myeloid Leukemia
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study in AML patients is to test whether vadastuximab talirine (SGN-CD33A; 33A) combined with either azacitidine or decitabine improves remission rates and extends overall survival as compared to placebo…
- Trial name
- CASCADE (NCT02785900)
- Testing
- 33A, azacitidine, decitabine
- Where
- 128 sites in United States, Australia and 14 more
- Volunteers
- 240 people
- Sponsor
- Seagen Inc.
Acute Myeloid Leukemia, Induction Chemotherapy
Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60
The purpose of this study is to evaluate the safety and efficacy of DAC combined with HAAG regimen in the induction treatment of newly diagnosed AML patients older than 60 years.
- Trial name
- NCT04083911
- Testing
- Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Colorectal Cancer Metastatic
Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）
This study investigates the efficacy and safety of sintilimab in combination with bevacizumab and decitabine for patients with advanced proficient mismatch repair/microsatellite stable (pMMR/MSS) colorectal cancer who have…
- Trial name
- NCT07007767
- Testing
- sintilimab, Bevacizumab Biosimilar, Decitabine
- Volunteers
- 32 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Esophageal Squamous Cell Carcinoma
Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
The purpose of this study is to observe and evaluate the efficacy and safety of Decitabine plus Penpulimab as second-line therapy for advanced esophageal squamous cell carcinoma treated with PD-1 blockade
- Trial name
- NCT05265962
- Testing
- Decitabine plus Penpulimab
- Volunteers
- 85 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is among the most common hematologic malignancies in adults and accounts for approximately 10,000 deaths in the United States every year. AML is commonly diagnosed in sixth or seventh decades of life.
- Conditions
- Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Trial name
- NCT03226418
- Testing
- Cytarabine, Decitabine, Idarubicin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Nebraska
Myelodysplastic Syndromes (MDS)
A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)
To evaluate the safety and clinical efficacy of ultra-low-dose decitabine in Chinese MDS
- Trial name
- NCT02779569
- Testing
- decitabine
- Where
- 6 sites in China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of TK216 and decitabine when given together in treating patients with acute myeloid leukemia that has come back or does not respond to treatment.
- Trial name
- NCT03752138
- Testing
- Group 1: TK216, Group 2: TK216, Part 2: Decitabine 10mg/m2
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukaemia, Myelodysplastic Syndrome
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations
The AML18 Trial will evaluate several relevant therapeutic questions in Acute Myeloid Leukaemia (AML), as defined by the WHO, and High Risk Myelodysplastic Syndrome.
- Trial name
- AML18 (NCT02272478)
- Testing
- Arm A Mylotarg plus DA Versus CPX-351, Arm B Vosaroxin and Decitabine, Arm D Small molecule or Not
- Where
- 87 sites in Denmark, United Kingdom
- Volunteers
- 1,600 people
- Sponsor
- Cardiff University
Acute Myelogenous Leukemia
Epigenetic Reprogramming in Relapse/Refractory AML
This is a pilot study using decitabine and vorinostat before and during chemotherapy with fludarabine, cytarabine and G-CSF (FLAG).
- Trial name
- NCT03263936
- Testing
- Decitabine, Vorinostat, Filgrastim (G-CSF)
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 37 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
This phase II trial tests if adding pacritinib to standard of care azacitidine or decitabine increases the number of patients able to proceed to hematopoietic stem cell transplantation (bridging) for patients with accelerated and…
- Trial name
- NCT07148947
- Testing
- Pacritinib, Decitabine, Decitabine and Cedazuridine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Washington
SMD
GFM-Acadesine: A Phase I-II Trial of Acadesine
A phase I-II trial of Acadesine in IPSS high and int 2 myelodysplastic syndromes, acute myeloid leukemia with 20-30% marrow blasts and chronic myelomonocytic leukemia type 2 not responding to Azacitidine or Decitabine for at…
- Trial name
- Acadesine (NCT01813838)
- Testing
- ACADESINE 140mg/kg/d, ACADESINE 210mg/kg/d, ACADESINE 315mg/kg/d
- Where
- 17 sites in France
- Volunteers
- 5 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Systemic Mastocytosis With an Associated Hematologic Neoplasm
Avapritinib With Decitabine in Patients With SM-AHN
Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this indication based on their ability to control the mastocytosis portion…
- Trial name
- NCT06327685
- Testing
- Avapritinib, Decitabine, Decitabine/Cedazuridine
- Where
- 7 sites in United States
- Volunteers
- 34 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Relapsed/Refractory Non-Hodgkin Lymphoma, Advanced Solid Tumors
Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors
This phase I/II trial aims to evaluate safety and efficacy of Chidamide, Decitabine and Immune checkpoint inhibitors in relapsed/refractory Non-Hodgkin Lymphoma and advanced solid tumors.
- Trial name
- NCT05320640
- Testing
- Chidamide, Decitabine, Immune checkpoint inhibitors（anti-PD1/PD-L1/CTLA4 antibodies）
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
This phase II trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms (MPNs).
- Conditions
- Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT06661915
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 31 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
To learn if giving the study drugs calaspargase pegol-mknl and decitabine in combination with venetoclax can help to control relapsed/refractory T-ALL and T-LLy. The safety of this drug combination will also be studied.
- Trial name
- NCT06561074
- Testing
- Decitabine, Venetoclax, Calaspargase pegol-mknl
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
This is a study to evaluate PF-04449913 (an inhibitor of the Hedgehog pathway) in Acute Myeloid Leukemia and high-risk Myelodysplastic Syndrome in combination with standard agents used to treat these diseases.
- Trial name
- NCT01546038
- Testing
- PF-04449913, Low dose ARA-C (LDAC), Decitabine
- Where
- 81 sites in United States, Canada and 4 more
- Volunteers
- 255 people
- Sponsor
- Pfizer
Malignancy
Treatment of Malignant Tumors With NK Cell
Natural killer cells (NK cells) are derived from bone marrow lymphoid stem cells, which are a type of lymphocytes that can non-specifically kill tumor cells and virus-infected cells without pre-sensitization.
- Trial name
- NK cell (NCT05143125)
- Testing
- Decitabine combined with NK cell infusion
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen University General Hospital
Liver Metastasis, Colorectal Cancer
Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)
Despite the advances in the medical treatment of unresectable liver metastases from colorectal cancer there is currently no curative treatment option available for these patients.
- Trial name
- DECIT (NCT02316028)
- Testing
- Decitabine
- Where
- 2 sites in Belgium
- Volunteers
- 11 people
- Sponsor
- Universitair Ziekenhuis Brussel
Myelodysplastic Syndromes
PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes
This is an Open-Label, Crossover, Pharmacokinetic and Efficacy Bridging Study of Oral ASTX727 versus IV Decitabine in Chinese Subjects with Myelodysplastic Syndromes
- Trial name
- NCT06091267
- Testing
- IV Decitabine, Decitabine and cedazuridine, only Decitabine and cedazuridine
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Otsuka Beijing Research Institute
Acute Myeloid Leukemia, Adult
Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult
This study proposes to conduct a prospective, multicenter, single-arm study to explore the efficacy and safety of venetoclax in combination with high-dose decitabine (DEC3-VEN) in new diagnosed adult patients with AML, and to…
- Trial name
- NCT06285136
- Testing
- DEC3-VEN
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The Second Affiliated Hospital of Kunming Medical University